NCT00414947已完成1 期
A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. to imported vildagliptin tablet in Chinese healthy subjects
研究概览
简要总结
This study will evaluate the bioequivalence as well as rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. compared to the imported vildagliptin tablet in Chinese healthy volunteers.
This trial is not recruiting patients in the United States,
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Chinese healthy male subjects age 18 to 40 years of age included
- •In good health
- •Male subjects using a double-barrier local contraception for the entire duration of the study up to study completion visit and refraining from fathering a child in the three months following last study drug administration.
- •Body mass index within the range of 19 to 24 kg/m2 and weigh at least 50 kg
排除标准
- •Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Paracetamol is acceptable.
- •Participation in any clinical investigation within 4 weeks prior to dosing.
- •Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- •Significant illness within two weeks prior to dosing.
- •A past personal or close family medical history of clinically significant cardiac abnormalities.
- •History of:
- •Fainting, low blood pressure when standing, irregular heartbeats,
- •Acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated),
- •Clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis)
- •Known hypersensitivity to the study drug or similar drugs
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or jeopardize participation in the study.
- •Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
- •Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- •Drug or alcohol abuse within the 12 months prior to dosing
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. to imported vildagliptin tablet in Chinese healthy subjects
次要结局
- Safety and tolerability of vildagliptin tablet after a 50 mg single dose
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00368134Novartis370
尚未招募
1 期
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) TabletsHealthy SubjectsNCT06248801Bio-innova Co., Ltd48
已完成
1 期
Phase 1 Bioavailability Study of SYR-322METHealthy VolunteersNCT02508168Takeda24
已完成
1 期
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μgBioequivalenceNCT02206295Actelion80
已完成
1 期
Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese VolunteersHealthyNCT00419887Novartis60